Cyrcadia Health Expands Advisory Board with Nationally Recognized Author and Sports Business Advisor Mandy Antoniacci

Share Article

Magazine Columnist, Sports Business Advisor and Advocate for Social Change Fills Key Position for Cyrcadia

The data we are now able to capture will only further aid to empower women and help us regain the loss of control that we often feel when we are confronted with a health issue

Cyrcadia Health, awarded the 2016 Gold Edison Award as Top Healthcare Wearable for its early breast cancer screening technology, is pleased to announce the addition of Mandy Antoniacci to serve as sports business advisor and women’s health advocate for Cyrcadia. As an in-demand speaker and nationally recognized author whose published works have been featured in Inc., Business Insider, Huffington Post, Yahoo Sports and Yahoo Finance, Antoniacci fuses her extensive marketing and advertising experience in the fields of sports, technology and health and wellness to advocate social change in business.

“Is a great honor to have Mandy fill such a key role in our business advisory role,” said Rob Royea, president of Cyrcadia. “Her success in both business and in public communications within professional sports, as well as her passion to serve the underserved, will help to accelerate our message about the empowerment of women taking control over their individual personal health knowledge. Mandy’s personal understanding of the impact of breast cancer brings a unique ownership to our cause, which will help in her ability to passionately spread our key message to all women, medical professionals and financial and strategic supporters.

Antoniacci is also an advocate for women in her work as a Leadership Committee Member for the nonprofit Futures Without Violence, where she advises on policy and education for domestic violence prevention in conjunction with the National Football League and Major League Baseball. In her role at Cyrcadia, Antoniacci will help to lead the communication of Cyrcadia’s vision to empower women to take control of their own breast health knowledge through wearable devices, such as Cyrcadia’s iTBra™, and to improve their understanding of breast cancer.

“The iTBra for me represents the ultimate convergence of my personal and professional life,” said Antoniacci. “I have such a strong family history of breast cancer, including my mother, aunt, great aunt and even my own benign lumpectomy when I was 21 years old. This deep-rooted relationship with the disease, coupled with my business acumen in the sports business landscape, presents a rare and blessed opportunity for me.”

One in eight women in the U.S. are diagnosed with breast cancer annually, and approximately 500,000 women die worldwide from the disease each year, many due to lack of early detection. Cyrcadia’s wearable, smart phone-enabled iTBra technology, uses a comfortable data collection device placed under a bra to collect from two to twelve hours of breast cell data (dynamic cell chaos). Circadian rhythm-based variances of cell cycles are then measured through a Cyrcadia-patented process to identify abnormalities at the earliest stages of cellular change over time, the results of which can be automatically communicated to the woman physician to provide the earliest possible diagnosis of breast cancer.

According to Antoniacci, the growth in the wearable tech sector in women’s health in particular has progressed astronomically and will continue to do so at an exponential pace. “The data we are now able to capture will only further aid to empower women and help us regain the loss of control that we often feel when we are confronted with a health issue.”

Cyrcadia is currently conducting a 173 patient trial at El Camino Hospital, Mountain View, California, and The Ohio State University, at the third-largest cancer hospital in the United States. Trials are extending to Stanford University’s Medicine X program, which will extend to a global program for early breast cancer screening for women of all ages, with a special emphasis on those with impoverished nations whose women have difficulty accessing healthcare until their conditions are far too advanced for effective treatment.

“Wearable device companies are looking at all of the critical imperatives for health and wellness - activity level, sleep, nutrition - and the connection to chronic disease (diabetes, heart disease, obesity, and more) that impact global populations,” said Antoniacci. “But the iTBra and this technology amplify that notion to a whole different level. On the business side of things, that excites me tremendously!”

Cyrcadia is initially targeting the 40% of women who have dense breast tissue. 28 states now mandate that physicians tell their patients that they have a dense breast condition, therefore a higher propensity for cancer, and that the current diagnostic modalities are challenged with their condition in which the tissue itself can mask cancer cells and lesions. Additionally, Cyrcadia intends to be a supplementary screening solution for those 70 percent of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, representing over 1.2 million biopsies for women on non-cancerous tissue annually.

“It is an honor and privilege to participate in the growth of a product that is truly the only life-changing wearable for women of its kind,” said Antoniacci. “Together, we can positively affect countless women and change the trajectory of my own personal and familial experiences. The ability to help lead that movement is something very special to me.”

About Cyrcadia, Inc.

Cyrcadia, Inc., also known as Cyrcadia Health, was founded as First Warning Systems in 2008, is based in Reno, Nev. The company’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia is underway in a final, limited clinical trial and a 510k device classification to validate the product. Cyrcadia technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO) Cyrcadia is preparing to apply for FDA Clearance and a Euro CE Mark to market in the European Union and Asia Pacific markets, with anticipation of launching its technology to market in 2017. Furthermore, Cisco Systems, Inc. has financially supported the making of a documentary by Ironbound Films about the evolution of Cyrcadia technology, called “Detected Movie” to be released. Please visit http://www.DetectedMovie.com and Cyrcadia Health at http://www.cyrcadiahealth.com.

Per Federal FDAAA 801 guidelines, Cyrcadia will release information on trial location additions, as well as clinical trial data only at time of trial completion or FDA clearance for disclosure.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laurie Hallwyler
ckj Communications
+1 650-248-9081
Email >

Laurie Hallwyler
Visit website